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Summary In this paper we investigate the reactivity pattern of T cells from stomach carcinoma patients
against autologous tumour cells. T cells obtained from the tumour environment, tumour-draining lymph nodes
and peripheral blood were cloned in 78 patients with stomach cancer and anti-tumour cytotoxic T lym-
phocytes (CTLs) precursor frequencies were assessed in each sample by using limiting dilution analysis. When
tumour-specific CTLs were tested for specific T-cell killing by using only low doses of Interleukin 2
(100 U ml-'), a moderate rate of proliferation frequency of T cells (0.047) and specific cytotoxicity (12%) were
observed in lymph node populations. When both IL-2 and autologous tumour cells in mixed lymphocyte
tumour cultures (MLTCs) were used for stimulation, a dramatic increase in number (0.1) and in specific lytic
activity (46%) could be measured. No effect or specific activity to tumour cells was observed with peripheral
blood lymphocytes and tumour-infiltrating lymphocytes.
Most investigations of T-cell reactivity to tumours have up
until now concentrated on melanomas. This is a good model
of cellular reaction to tumour-associated immunogenic struc-
tures (Anchini et al., 1987, 1989; Muul et al., 1987; Topalian
et al., 1989) and one in which immunotherapies have proved
effective (Rosenberg et al., 1986). Only a few other spon-
taneous tumours have been analysed, and only a few reports
(Nakamura et al., 1988; Mukhopadhyaya et al., 1989; Tatake
et al., 1989) have compared immune responses between lym-
phocytes isolated from peripheral blood, regional lymph
nodes and tumours in different malignant diseases. Most deal
with lymphokine-activated killer (LAK) cells (Itoh et al.,
1986; Rabinowich et al., 1987) and cytotoxic T lymphocytes
(CTLs) originating from melanomas (Muul et al., 1987;
Anchini et al., 1989; Topalian et al., 1989). In many cases, it
has been reported that tumours themselves (Miescher et al.,
1986; McLemore et al., 1988; Floutsis et al., 1989; Kuppner
et al., 1989, 1990) or tumour-infiltrating suppressor cells
(North et al., 1985; Mukherji et al., 1986a,b) inhibit the
proliferation and function of T lymphocytes. Herin et al.
(1987), Uchida et al. (1988) and Gervois et al. (1990) showed
in their experiments that mixed lymphocyte tumour cultures
(MLTCs) can propagate the growth of tumour-specific
cytotoxic T cells in vitro.
Stomach carcinoma is still one of the most frequent
cancers worldwide with a very poor prognosis (Correa, 1985)
and relatively unknown aetiology. Furthermore, most likely
owing to the long development of these spontaneous
tumours, a down-regulation of host immune response has
been observed (Whiteside et al., 1986; Miescher et al., 1987;
Belldegrun et al., 1988). The proliferation capacity of
immune cells from tumour patients seems to be very poor
(Miescher et al., 1988a,b), making it difficult to investigate
reactivity patterns of T cells from stomach cancer.
In this study we raised and analysed tumour-specific CTLs
obtained from stomach carcinoma patients.
Materials and methods
Patients
Seventy-eight different stomach tumour resections from 78
German patients between the ages of 29 and 83 (mean 65
years) were used in our study (Table I). We obtained only
one tumour from every patient. In 46 cases the clinical
resections included the spleen. From 64 patients lymph nodes
had been resected and from 14 we received no lymph node
material. Blood was obtained from 38 patients prior to oper-
ation. The lymphocytes from one source (tumour, blood,
spleen or lymph node) each tested as a separate population.
None of the patients had received chemotherapy before
resection.
Isolation oflymphocytes and tumour cells
Peripheral blood lymphocytes (PBLs) Heparinised blood
obtained prior to the operation was diluted 1:1 with RPMI-
1640 (Biochrom, Germany). Mononuclear cells were isolated
by Ficoll-Hypaque (Biochrom) density gradient. A 25 ml
volume of diluted blood overlayered on 15 ml of Ficoll
(D = 0.0177) was centrifuged at 700g for 20 min at room
temperature. Cells from the interphase were collected and
washed twice in RPMI-1640.
Regional lymph node lymphocytes (RLNLs) Regional lymph
nodes, harvested from resection, were minced and pressed
through a 100 gm nylon mesh (Nybolt, Switzerland). The
suspended cells were washed twice in 10 ml of RPMI + 10%
fetal calf serum (FCS) (Biochrom) + 50 sgml-' gentamycin
(Biochrom).
Tumour-infiltrating lymphocytes (TILs) The tumour pieces
from 78 tumours were minced, crushed on a glass slide,
passed through a 100iLm stainless-steel mesh and washed in
phosphate-buffered saline (PBS) according to the method of
Vose (1982). The remaining tissue was treated with col-
lagenase II (Sigma, Germany) and DNAse I (Sigma) accord-
ing to Slocum et al. (1983). Cell suspensions were then
Table I Total number of stomach cancer cases analysed
Sex Mean Tumour grade'
Tumour type" Number (malek/female) age GI G2 G3 G4
Signet ring 6 2/4 58.0 - 1 3 2
Carcinoma
Undifferentiated 20 13/7 62.7 - 2 10 8
Carcinoma
Adenocarcinoma 52 34/18 68.0- 6 22 21 3
aTumour type assigned was according to the WHO histological
classification of malignant tumours of the stomach. "Tumour grade
was histopathologically determined according to cellular
components, with GI indicating a well-differentiated, G2 a
moderately well-differentiated and G3-G4 a poorly to very poorly
differentiated adenocarcinoma.
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layered on a two-step Ficoll-Hypaque gradient (100% Ficoll
and 33% Ficoll in RPMI). The cells were centrifuged for
30 min at 400 g. Tumour cells were found in the interphase
of 33% Ficoll dilution. Between 20 and 87% (mean 47%,
determined from May-Griinwald-Giemsa-stained cytospins)
of cells harvested at the 100% Ficol interphase were lym-
phocytes (TILs). These TILs were resuspended in RPMI +
10% FCS for later use in limiting dilution and MLTCs.
Tumour cell culture
Freshly isolated tumour cells were transferred to 500 ml plas-
tic culture flasks (Greiner, Germany) and incubated for
30 min at 37°C to remove the macrophages and majority of
fibroblasts by adherence on the plastic surface. Then
0.5 x 106 non-adherent cells were cultured in a 25 ml culture
flask (Greiner) in RPMI-1640 supplemented with 10% FCS
and antibiotics to obtain permanent tumour cell lines. The
remaining tumour cells were frozen and stored in liquid
nitrogen. Immunohistological studies had shown that the
tumour cells were contaminated with 10-20% remaining
fibroblasts. When needed for stimulation and targets in 5'Cr-
release assay, tumour cells were washed and irradiated (5,000
rad).
Tumorigenicity, immunohistochemical studies and
biochemical analysis of the six established tumour cell lines
were as described by Vollmers et al. (1993).
Mixed lymphocyte tumour cultures
To select tumour specific T cells, we modified the method of
Uchida et al. (1988) and Herin et al. (1987) who used
autologous tumour cells for stimulation. From one tumour
(23132) and from five lymph node metastases we derived
stable tumour cell lines to use in co-culturing. MLTCs were
layered out from every tumour by using 24-well flat-
bottomed tissue culutre plates (Greiner) with 1 x 106 res-
ponder and 1 x 105 irradiated (5,000 rad) autologous tumour
cells (10:1). The cells were mixed in final volume of 2 ml of
RPMI + 10% FCS and 1% gentamicin. On day 3 50 IU ml-'
recombinant IL-2 was added. On day 7 the growing cells
were collected, washed and incubated with fresh irradiated
tumour cells (2 ml of medium containing 50 IU ml- ' rIL-2).
On day 14 lymphocytes were washed, counted, phenotyped
by monoclonal antibody OKT3 (Ortho Diagnostics, Ger-
many) and later used in limiting dilution experiments.
Cell cloning by limiting dilution
All lymphocytes were phenotyped by monoclonal antibody
OKT3. Cloning by limiting dilution of T cells was performed
according to the method of Moretta et al. (1982). Clones
were established from fresh PBLs, RLNLs or TILs and after
MLTCs. Microcultures of all lymphocytes were grown in
96-well round-bottomed microtitre plates (Greiner). From
each of the 78 patients only one cloning of each different
lymphoid source was performed. Four 96-well plates were
seeded per cloning, one with 1, one with 3, one with 10 and
one with 30 cells per well seeded in 200 sl of complete
medium containing 50 IU ml-' rIL-2 and I% phytohaemag-
glutinin (PHA) (Gibco, Germany), supplemented weekly with
1 x 105 irradiated feeder cells (allogeneic spleen cells)
suspended in 100 pi of medium with IL-2 and in six cases
with 1 x 103 irradiated autologous tumour cells. After 3
weeks the growing responder cells were transferred to 96-well
flat-bottomed microtitre plates (200 lal of medium supple-
mented with 50 IU ml-' rIL-2, feeder cells and in six cases
with 1 x 103 irradiated autologous tumour cells). Expanding
microcultures were plated on 24-well tissue culture plates
(Greiner), evaluated for their phenotype and functionally
tested in chromium-release assay (Brunner et al., 1976)
against five allogeneic tumour target cells, autologous tumour
cells and PHA-blasts and K562 cells.
Owing to the low proliferative T-cell precursor frequency
obtained in these samples, and according to a formula des-
cribed in Taswell et al. (1980), explanded microcultures were
operationally defined as clones.
Determination offrequencies ofproliferating T-cellprecursors
by limiting dilution analysis
Precursor frequencies were obtained by calculating and draw-
ing a straight line which describes the relationship between
number of seeded cells per well and the logarithm of the
fraction of non-proliferating (negative) microcultures. Ac-
cording to the single-hit Poisson model, the cell dose (x-axis)
containing on the average one proliferating T cell is given by
the intercept of the straight titration line by the ordinate
value 0.37. Positive/negative responses were the presence/
absence of growing T cells in a well at the highest three
dilutions. Results were calculated using a program estab-
lished and described in more detail by Taswell (1981).
Culture of T-cell clones
Obtained clones were cultured in RPMI with 10% FCS and
antibiotics supplemented with 50 IU ml-' rIL-2. The addition
of irradiated (5,000 rad) autologous tumour cells every 2
weeks in an effector-target (E/T) ratio of 10: 1 was necessary
to maintain growth of the specific clones.
Target cells
Six different stomach carcinoma cell lines, the natural killer
cell (NK)-sensitive cell line K562 and the NK-resistant cell
line Daudi were used as allogenic target cells in cytotoxic
assay and MLTC (Table II). All lines were obtained from
metastatic stomach tumours after isolation and culturing as
described above. PHA-blasts were generated by stimulation
of freshly isolated autologous lymphocytes from blood or
spleen in medium supplemented with 1% PHA (Gibco) for 3
days, washed and used as target cells after labelling with
5'Cr.
Cytotoxic assay
The cytotoxic activity of T-cell clones was tested for
cytotoxic activity against 5'Cr-labelled target cells according
Table II Tumour cell lines used in mixed lymphocyte tumour culture
Number Sex of Age of Tumour Tumour Tumour Tumour cell
of tumour patient patient typea stageb gradec origin
114 Female 54 Signet ring T4 NI Ml G3 Primary tumour
200 Female 44 Signet ring T4 NI MO G4 Primary tumour
2474 Male 60 Adenocarcinoma TI N2 MI G2 Metastasis
2957 Male 51 Adenocarcinoma T2 N2 MO G3 Metastasis
3051 Male 62 Adenocarcinoma T4 N2 MO G3 Metastasis
23132 Male 72 Adenocarcinoma T2 NO MO G3 Primary tumour
aTumour type was assigned according to the WHO histological classification of malignant tumours
of the stomach. "Tumour stage proposed by the American Joint Committee on Cancer, based on the
TNM classification. cTumour grade was histopathologically determined according to cellular
components, with G1 indicating a well-differentiated, G2 a moderately well-differentiated and G3-G4
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to the method of Brunner et al. (1976). Target cells were
incubated with 0.2 mCi of sodium 5"chromate (Amersham,
Germany) at 37°C for 90 min in medium containing 10%
FCS. After washing twice, 0.1 ml of medium containing
1 x 104 tagret cells were added to each well of 96-well V-
bottomed plates (Greiner). Three different amounts of
effector cells were added to the target cells (E/T ratios) in a
volume of 100 p1. The plates were centrifuged at 65g for
3 min and incubated at 37'C for 4 h. Supernatants were
transferred manually to counting vials (Greiner) and counted
in a -y-counter (Beckman, Germany). All determinations were
performed in triplicate. Spontaneous release was calculated
by incubating the targets with medium alone. Maximum
release was obtained from wells incubated with 5% Triton
X-100. Spontaneous release of the carcinoma target cells and
spleen cells ranged between 10 and 20% of the maximum
release. The percentage of specific lysis was determined as:
Experimental mean c.p.m. - spontaneous release mean c.p.m.
Maximum mean c.p.m. - spontaneous release mean c.p.m.
Flow cytometry
T-cell clones were stained with monoclonal antibodies anti-
CD3, anti-CD4, anti-CD8, anti-CD25 and anti-TCR o/p
(Becton-Dickinson, USA). T-cell clones were incubated for
45 min on ice in PBS-sodium acid together with the primary
monoclonal mouse antibody. After washing three times with
PBS, the cells were incubated for 30 min on ice in fluorescein
isothiocyanate (FITC)-conjugated rabbit anti-mouse [F(ab')2
fraction] Dakopatts, Denmark), washed again three times
with PBS and stored on ice. Cells were analysed for FITC
fluorescence (at 495 nm) by flow cytometry using a FACS
System (Becton Dickinson) and a computer-controlled pro-
gram, FACSSCAN 2.1 (Hewlett-Packard) for quality an-
alysis.
Proliferation assay of T-cell clones after stimulation with
tumour cells
Proliferation of tested T-cell clones (5 x 103per well) was
examined by incubation with various irradiated (5,000 rad)
target cells in different ratios (10:0 to 10:1 clone target cell
ratio). Approximately 5 x 103 T cells were incubated for 3
days with different numbers of target cells in medium with
n=0 n=0
-C, * . .
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Figure 1 Specific cytotoxic activity of T-cell clones against auto-
logous tumour cells from different lymphocyte sources from six
stomach cancer patients. RLNLs, regional lymph node lympho-
cytes from four samples; TILs, tumour-infiltrating lymphocytes
from six samples; PBLs, peripheral blood lymphocytes from five
samples; all cloned prior to and after autologous mixed lym-
phocyte tumour culture (MLTC). n, number of grown and tested
cytotoxic T-cell clones. Specific cytotoxic activity was determined
by lysing more than 10% of the autologous tumour cells in a 4 h
5'Cr-release assay. The effector-target (E/T) ratio used was 10:1.
Data shown are means, bars are s.d.
10% FCS and 10 units ml-' IL-2 in flat-bottom 96-well
plates. The wells were pulsed with 1 plCi of [3H]thymidine
(Amersham) and incubated for 18 h at 37°C. The DNA of
cells was harvested and measured in liquid scintillation fluid
in a Hewlett-Packard scintillation counter. All determinations
were performed in triplicate.
Blocking experiments
The T-cell clones were incubated with various concentration
(0.1-10Ag ml-') of anti-CD3 (Leu4, Becton Dickinson) and
anti-CD8 (Leu 2a, Becton Dickinson) for 30 min at 37°C.
Then they were added to the 51Cr-labelled target cells in
standard cytotoxic assay:
( % specific lysis in MAb-treated wells A
% specific lysis in control wells 1
Tumour cells (23132) were incubated with anti-HLA-ABC
[OKDR (Ortho) and anti-HLA-DR MAb (Becton Dickin-
son)] used at a final dilution of 1:10 to 1:5 for 30 min at
37'C and used as target cells in a cytotoxic assay.
Statistical analysis
Differences between experimental data and control data were
analysed by Student's t-test. The significance level was set at
P<0.05.
Results
Specific cytotoxicity
The recovery of lymphocytes differed in all 78 biopsies (from
0.3 x 106 to 1.6 x 107). We could not observe any correlation
between type and stage of tumour, age of the patient and
yield of viable lymphocytes. The main point of our investiga-
tion was to establish T-cell clones with the ability to lyse
specifically autologous tumour cells (Figure 1). No lysis of
allogeneic tumour cells and autologous blasts could be
detected.
We found these specific cytotoxic T-cell clones in all six
tested patients in the lymph node compartment. Prior to
co-culturing, the frequency of cytotoxic precursor T cells in
RLNLs reached the level of 0.047 (16 clones, Figure 2) and
the specific lysis of these T-cell clones was very low (12%,
E/T ratio 10:1; Figure 1. NK activity measured by lysis of
NK-sensitive cell line K562 reached 21%.
However, cloning after MLTC resulted in an increase in
frequency (up to 0.1, 35 clones; Figure 2) and in the lysis of
the autologous tumour cells (up to 47%; Figure 1) by specific
T-cell clones. Moderate NK activity of 11% could be
detected. We observed this effect only with lymph node
lymphocytes. In PBLs or TILs using the same cloning condi-
tions and cloning prior to and after MLTCs, we found no
T-cell clones with specific lysis. Only a few clones with
unknown specificity will grow.
Limiting dilution
Limiting dilution analysis was used to calculate the prolifera-
tion capacity of T cells from different sources with the fol-
lowing results. The frequency of proliferating T cells in the
TIL fraction was moderate - often less than 3% (F = 0.03) of
cells were able to proliferate. In contrast to TILs, lym-
phocytes from regional lymph nodes showed a higher rate of
proliferating T cells (8 to 10-fold). A reduced ratio growth
(F = 0.17) could also be observed in patients' PBLs as com-
pared with 50-100% (mean = 0.73) in normal control PBL T
cells (Figure 3).
No influence of MLTC on precursor frequency of T cells
could be observed in RLNLs.
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Subpopulations
The lymphocyte subpopulations before or after MLTCs in
stomach cancer differed significantly. We observed a change
from CD4+ cells to CD8+ cells by co-culturing lymphocytes
with autologous tumour cells. The number of CD8-positive
T-cell clones increased after MLTC in all cultures (Table III).
All cell clones were CD3 positive. Four clones tested with
antibodies against the oc/p-chain and y/6-chain ofT-cell recep-
tor all showed the cx/p T-cell receptor type.
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Figure 2 Frequency analysis of proliferating CTL precursors
from six stomach cancer patients. RLNLs, regional lymph node
lymphocytes from four samples; TILs, tumour-infiltrating lym-
phocytes from six samples; PBLs, peripheral blood lymphocytes
from five samples; all cloned prior to and after autologous mixed
lymphocyte tumour culture (MLTC). CTLs were determined by
lysing more than 10% of the autologous tumour cells in a 4 h
5'Cr-release assay. The effector-target (E/T) ratio used was 10:1.
Frequency was calculated by limiting dilution analysis as des-
cribed in detail in the Materials and methods section. Data
shown are means, bars are s.d.
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Figure 3 Frequency analysis of proliferating T-cell precursors
from different lymphocyte sources from stomach cancer patients.
RLNLs, regional lymph-node lymphocytes (64 samples); TILs,
tumour-infiltrating lymphocytes (78 samples); PBLs, peripheral
blood lymphocytes (38 samples); control PBLs, control peripheral
blood lymphocytes from control group (18 samples). Frequency
was calculated by limiting dilution analysis as described in detail
in the Material and methods section. Data shown are means, bars
are s.d.
Immunofluorescence analysis of a stimulated T-cell clone
The expression of IL-2 receptor increased only on stimula-
tion with autologous tumour cells (Figure 4d). With medium
alone (Figure 4a) with the autologus EBV cell line (Figure
4b) or with the allogenic tumour cell line 23132 (Figure 4c)
no or limited stimulation could be observed.
Proliferation ofclones after stimulation with different cells
We tested four resting clones from patient 23132 derived
from the lymph node compartment. After stimulation with
autologous tumour cells we could detect proliferation ex-
pressed by incorporation of [3H]thymidine (Figure 5). The
stimulations culminated in a maximum proliferation response
of stimulated clones at a ratio between 1: 1 and 5:1 responder
cells to tumour cells. We observed no effect by adding
allogenic tumour cells or autologous spleen cells.
Restimulation of the clones with autologous tumour cells
was necessary to produce proliferating cells. The application
of low-dose IL-2 (10 U ml-') alone was not sufficient to
obtain highly proliferating clones. This means that the pro-
liferation of these specific cytotoxic T cells is dependent on
IL-2 production of stimulated associated T-helper clones.
Blocking experiments ofspecific cytotoxicity with monoclonal
antibodies
Different monoclonal antibodies were used to block the
specific lysis of the autologous tumour cells by the four
investigated T-cell clones to detect the restriction elements of
binding of these clones to the target cells. The upper graph in
Figure 6 shows the blocking efficiency of the antibodies
against the T-cell receptor-associated protein CD3 and the
CD8 protein. We observed similar blocking effects with both
antibodies.
Preincubation of the tumour cells with antibodies against
MHC class I (HLA-ABC) reduced the cytotoxicity drama-
tically (Figure 6, lower graph). The antibody against class II
showed no blocking effects.
Discussion
This is the first study analysing T-cell reactions in stomach
cancers under cloning conditions. We were able to show that
it is possible to expand CD8+ T-lymphocyte clones specific
for autologous tumour cells with high levels of lytic activity.
Only in cultures of human lymph node lymphocyte popula-
tions and with mixed lymphocyte tumour cultures could
specific cytotoxic clones be generated.
Many authors describe the low proliferation frequency in
different types of tumour (Whiteside et al., 1986; Miescher et
al., 1987; Belldegrun et al., 1988; Anchini et al., 1989). Using
immunohistochemical techniques we observed either a loss of
or low levels of IL-2 receptor in TILs in the tumours (data
not shown).
The low capacity for proliferation of lymphocytes from
Table III Phenothyping of T-cell clones from six patients and different sources cloned prior to or
after mixed lymphocyte tumour culture
Prior to MLTC After MLTC
Lymphocyte Number of Clones CD4+/CD8+ Clones CD4+/CD8+
subpopulations clonings CD4+/CD8+ ratio CD4+/CD8+ ratio
TILs 6 11/4 2.7/1 5/9 1/1.8
RLNLs 4 50/23 2.17/1 16/35 1/2.13
PBLs 5 39/18 2.17/1 23/32 1/1.4
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Figure 5 Proliferation of four T-cell clones in response to auto-
logous cells (*, 200 spleen), tumour cells (U, 200 tumour cells)
and allogenic tumour cells of the same (@, 114 tumour cells) and
different histology (A, 23132 tumour cells). Proliferation ofT-cell
clones (5 x 103) was examined by [3H]thymidine incorporation
after co-culturing for 3 days with the irradiated target cells and
application of 10UmlmL IL-2. T-cell clone - target cell ratio
ranged from 10:0 (T-cell clone alone with medium) to 10:1.
70 -
60 -
50
40 -
30
20
010
CO
.Fa 0
80
C.)
70-
(n
60 104
Figure 4 FACS analysis of IL-2 receptor (Tac) expression of the
clone C2 after stimulation with allogenic and autologous tumour
cells. a, Medium alone; b, stimulated by an autologous irradiated
EBV cell line; c, stimulated by allogenic tumour cell line 23132; d,
stimulated by autologous tumour cell line 200.
cancer patients complicates the analysis of the T-cell reac-
tions. Our observations of low proliferation of all tested
lymphocytes from tumour patients confirmed the data from
Whiteside et al. (1986) and Miescher et al. (1987), who
investigated many different cancers. This could be due to the
presence of suppressor cells in the tumour environment, as
shown by North et al. (1986) in the mouse system and
Mukherji (1986a,b) in human melanoma-infiltrating T cells.
Other studies concentrate on immunosuppressive factors,
such as prostaglandin E2 (McLemore et al., 1988; Kuppner et
al., 1990) or transforming growth factor (TGF-P) (Kuppner
et al., 1989) secreted by tumour cells. In our system, super-
natants of tumour cell cultures were not seen to have any
influence on MLTCs on the proliferation of lymphocytes.
Using our stomach cancer cell lines (Vollmers et al., 1993)
in stimulation experiments, we were able to expand specific T
cells. We found no difference in proliferation frequency
between MLTCs and no co-culturing. This shows that the
tumour cells alone without the addition of cytokines could
not support growth of specific T cells. Lymphokines from
helper cells are necessary, and their help seems to be sup-
pressed also (Nagarkatti et al., 1990).
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Figure 6 Blocking experiments for cytotoxicity of four T-cell
clones with monoclonal antibodies. In a, T-cell clones were prein-
cubated with 0, 0.1 and 1 fig ml-' anti-CD3 (U) or anti-CD8 (A)
antibody for 30 min, then washed and used as effector cells. In b,
autologous tumour target cells were preincubated for 30 min with
monoclonal antibodies anti-HLA-BC (-) or HLA-DR (A) [dilu-
tion: medium alone (0), 1:10 and 1:5]. Cytotoxicity was measured
in a standarized 5'Cr-release assay. The effector-target (E/T) ratio
used was 10:1. All determinations were performed in triplicate
(details in Materials and methods.)
FACS analysis (Figure 4) of the specific T cells showed
that the expression of IL-2 receptor increased after stimula-
tion only with autologous tumour cells. This specificity could
also be shown in proliferation tests (Figure 5). Without
addition of IL-2 only a low rate of proliferation could be
observed, pointing to dependence on lymphokine production
of associated stimulated T-helper clones.
By using blocking experiments we could identify the
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restriction elements on the reacting T-cell clones as the T-cell
receptor (CD3) together with the CD8 molecule. This com-
plex reacts with the HLA-ABC surface antigen and an
unknown tumour antigen on the target tumour cells. Wolfel
et al. (1989) were able to identify HLA-A2 as the restricting
element for lysis melanoma by specific T-cell clones in their
study. Furthermore, Van der Bruggen et al. (1991) described
the first gene encoding a melanoma-specific antigen called
MAGE-1 which is restricted by HLA-A1.
We found tumour-specific T cells only in lymph nodes and
not in the tumour or in the blood. This is probably due to
suppressor factors produced by tumour cells and released in
the tumour microenvironment which suppress the prolifera-
tion of tumour-specific T cells.
However, we did observe tumour-reactive T cells in
tumour-draining lymph nodes. We think that tumour cells
might have a stimulating effect on specific T-cell immunity,
but we could only select these cells by MLTCs. Further
investigations are needed to prove this theory.
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